⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7136008 | 0.84 | NPC1 (0.54) | — | |
| SCHEMBL13763536 | 0.81 | NPC1 (0.59) | — | |
| SCHEMBL30203797 | 0.77 | — | — | |
| SCHEMBL28322436 | 0.77 | — | — | |
| SCHEMBL80955 | 0.77 | — | — | |
| SCHEMBL1466424 | 0.77 | — | — | |
| SCHEMBL4730487 | 0.77 | — | — | |
| SCHEMBL4748421 | 0.77 | GAA (0.48) | — | |
| SCHEMBL5778325 | 0.77 | RAB9A (0.47) | — | |
| Hydrochloric Acid SCHEMBL7237591 | 0.76 | NPC1 (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024131265-A1 | COMPOUND FOR TREATING PI3Kγ-MEDIATED DISEASES AND USE THEREOF | 中国科学院合肥物质科学研究院 | 2024-06-27 | — | — | WO | claimed |
| CN-118239953-A | Compounds for the treatment of PI3K gamma mediated diseases and uses thereof | 中国科学院合肥物质科学研究院 | 2024-06-25 | — | — | CN | claimed |
| US-RE49481-E1 | Compounds for the treatment and prophylaxis of respiratory syncytial virus disease | HOFFMANN-LA ROCHE INC. (US) | 2023-04-04 | — | — | US | claimed |
| EP-2742039-B1 | COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS DISEASE | HOFFMANN LA ROCHE (CH) | 2015-09-16 | — | — | EP | claimed |
| US-8871756-B2 | Compounds for the treatment and prophylaxis of Respiratory Syncytial Virus disease | HOFFMANN-LA ROCHE INC. (US) | 2014-10-28 | — | — | US | claimed |
| EP-2742039-A1 | COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS DISEASE | F. Hoffmann-La Roche AG (CH) | 2014-06-18 | — | — | EP | claimed |
| US-20130196974-A1 | COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS DISEASE | HOFFMANN-LA ROCHE INC. | 2013-08-01 | — | — | US | claimed |
| WO-2013020993-A1 | COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2013-02-14 | — | — | WO | claimed |
| US-8063221-B2 | Aminoquinolones as GSK-3 inhibitors | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2011-11-22 | — | — | US | claimed |
| EP-2164833-A2 | QUINAZOLINAMIDE DERIVATIVES | Merck Patent GmbH (DE) | 2010-03-24 | — | — | EP | claimed |
| WO-2009010139-A2 | QUINAZOLINAMIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2009-01-22 | — | — | WO | claimed |
| EP-2013182-A2 | AMINOQUINOLONES AS GSK-3 INHIBITORS | Activx Biosciences, Inc. (US) | 2009-01-14 | — | — | EP | claimed |
| US-20070254866-A1 | Aminoquinolones as GSK-3 inhibitors | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2007-11-01 | — | — | US | claimed |
| WO-2007106537-A2 | AMINOQUINOLONES AS GSK-3 INHIBITORS | ACTIVX BIOSCIENCES, INC. (US) | 2007-09-20 | — | — | WO | claimed |
| US-6610665-B1 | Treatment of inflammatory diseases, asthma or chronic obstructive pulmonary disease | SMITHKLINE BEECHAM CORPORATION | 2003-08-26 | — | — | US | claimed |
| EP-1056759-B1 | 2-(PURIN-9-YL) -TETRAHYDROFURAN-3, 4-DIOL DERIVATIVES | GLAXO GROUP LTD (GB) | 2002-09-04 | — | — | EP | claimed |
| WO-2024131265-A1 | COMPOUND FOR TREATING PI3Kγ-MEDIATED DISEASES AND USE THEREOF | 中国科学院合肥物质科学研究院 | 2024-06-27 | — | — | WO | disclosed |
| CN-118239953-A | Compounds for the treatment of PI3K gamma mediated diseases and uses thereof | 中国科学院合肥物质科学研究院 | 2024-06-25 | — | — | CN | disclosed |
| EP-0888344-A1 | SPIROCYCLE INTEGRIN INHIBITORS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1999-01-07 | — | — | EP | disclosed |
| WO-1997033887-A1 | SPIROCYCLE INTEGRIN INHIBITORS | DU PONT PHARMACEUTICALS COMPANY (US) | 1997-09-18 | — | — | WO | disclosed |